Aims Intravenous iron therapy can improve symptoms in patients with heart failure, anaemia and iron deficiency. The mechanisms underlying such an improvement might involve chemoreflex sensing and nocturnal breathing patterns. Methods and results Patients with heart failure, reduced left ventricular ejection fraction, anaemia (haemoglobin <13 g/dl in men; <12 g/dl in women) and iron deficiency (ferritin <100 or 100-299 mu g/L with transferrin saturation <20%) were 2:1 randomized to patient-tailored intravenous ferric carboxymaltose dose or placebo. Chemoreflex sensitivity cardiorespiratory sleep study, symptom assessment and cardiopulmonary exercise test were performed before and 2 weeks after the last treatment dose. Fifty-eight patients (38 active arm/20 placebo arm) completed the study. Intravenous iron was associated with less severe symptoms, higher haemoglobin (12.5 +/- 1.4 vs. 11.7 +/- 1.0 mg/dl, p < 0.05) and improved haematinic parameters. Ferric carboxymaltose improved the central hypercapnic ventilatory response (-25.8%, p < 0.05 vs. placebo), without changes in peripheral chemosensitivity. In particular, the central hypercapnic ventilatory responses passed from 4.6 +/- 6.5 to 2.9 +/- 2.9 L/min/mmHg after ferric carboxymaltose and from 4.4 +/- 4.6 to 4.6 +/- 3.9 L/min/mmHg after placebo (p(treatment*condition) = 0.046). In patients presenting with sleep-related breathing disorder, apnoea-hypopnoea index was reduced with active treatment as compared to placebo (12 +/- 11 vs. 19 +/- 13 events/h, p < 0.05). After ferric carboxymaltose, but not after placebo, both peak oxygen uptake (VO2) increased (Delta 1.1 +/- 2.0 ml/kg/min, p < 0.05) and VO2/workload slope was steeper (Delta 0.67 +/- 1.7 L/min/W, p < 0.01). Conclusions Intravenous ferric carboxymaltose improves the hypercapnic ventilatory response and sleep-related breathing disorders in patients with heart failure, anaemia and iron deficiency. These newly described findings, along with improved oxygen delivery to exercising muscles, likely contribute to the favourable effects of ferric carboxymaltose in anaemic patients with heart failure.

Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure / S. Caravita, A. Faini, C. Vignati, S. Pelucchi, E. Salvioni, G. Cattadori, C. Baratto, C. Torlasco, M. Contini, A. Villani, G. Malfatto, E. Perger, C. Lombardi, A. Piperno, P. Agostoni, G. Parati. - In: EUROPEAN JOURNAL OF HEART FAILURE. - ISSN 1388-9842. - 24:10(2022 Oct), pp. 1940-1949. [10.1002/ejhf.2628]

Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure

C. Vignati;E. Salvioni;G. Cattadori;G. Malfatto;A. Piperno;P. Agostoni
Penultimo
;
2022

Abstract

Aims Intravenous iron therapy can improve symptoms in patients with heart failure, anaemia and iron deficiency. The mechanisms underlying such an improvement might involve chemoreflex sensing and nocturnal breathing patterns. Methods and results Patients with heart failure, reduced left ventricular ejection fraction, anaemia (haemoglobin <13 g/dl in men; <12 g/dl in women) and iron deficiency (ferritin <100 or 100-299 mu g/L with transferrin saturation <20%) were 2:1 randomized to patient-tailored intravenous ferric carboxymaltose dose or placebo. Chemoreflex sensitivity cardiorespiratory sleep study, symptom assessment and cardiopulmonary exercise test were performed before and 2 weeks after the last treatment dose. Fifty-eight patients (38 active arm/20 placebo arm) completed the study. Intravenous iron was associated with less severe symptoms, higher haemoglobin (12.5 +/- 1.4 vs. 11.7 +/- 1.0 mg/dl, p < 0.05) and improved haematinic parameters. Ferric carboxymaltose improved the central hypercapnic ventilatory response (-25.8%, p < 0.05 vs. placebo), without changes in peripheral chemosensitivity. In particular, the central hypercapnic ventilatory responses passed from 4.6 +/- 6.5 to 2.9 +/- 2.9 L/min/mmHg after ferric carboxymaltose and from 4.4 +/- 4.6 to 4.6 +/- 3.9 L/min/mmHg after placebo (p(treatment*condition) = 0.046). In patients presenting with sleep-related breathing disorder, apnoea-hypopnoea index was reduced with active treatment as compared to placebo (12 +/- 11 vs. 19 +/- 13 events/h, p < 0.05). After ferric carboxymaltose, but not after placebo, both peak oxygen uptake (VO2) increased (Delta 1.1 +/- 2.0 ml/kg/min, p < 0.05) and VO2/workload slope was steeper (Delta 0.67 +/- 1.7 L/min/W, p < 0.01). Conclusions Intravenous ferric carboxymaltose improves the hypercapnic ventilatory response and sleep-related breathing disorders in patients with heart failure, anaemia and iron deficiency. These newly described findings, along with improved oxygen delivery to exercising muscles, likely contribute to the favourable effects of ferric carboxymaltose in anaemic patients with heart failure.
Anaemia; Chemoreflex; Exercise; Heart failure; Iron; Sleep
Settore MED/11 - Malattie dell'Apparato Cardiovascolare
ott-2022
22-lug-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
Solca+F+Eur+J+Neurol.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 866.02 kB
Formato Adobe PDF
866.02 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/956291
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
social impact